Amgen (XSGO:AMGN) Price-to-Operating-Cash-Flow : 16.19 (As of Apr. 24, 2024)

View and export this data going back to . Start your Free Trial

What is Amgen Price-to-Operating-Cash-Flow?

As of today (2024-04-24), Amgen's share price is $255.16. Amgen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $15.76. Hence, Amgen's Price-to-Operating-Cash-Flow Ratio for today is 16.19.

The historical rank and industry rank for Amgen's Price-to-Operating-Cash-Flow or its related term are showing as below:

XSGO:AMGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.31 Med: 13.37 Max: 20.51
Current: 17.36

During the past 13 years, Amgen's highest Price-to-Operating-Cash-Flow Ratio was 20.51. The lowest was 10.31. And the median was 13.37.

XSGO:AMGN's Price-to-Operating-Cash-Flow is ranked worse than
50.22% of 677 companies
in the Drug Manufacturers industry
Industry Median: 17.32 vs XSGO:AMGN: 17.36

Amgen's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $1.00. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $15.76.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Amgen was -12.40% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -4.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 0.20% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 5.80% per year.

During the past 13 years, Amgen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 239.80% per year. The lowest was -4.00% per year. And the median was 13.30% per year.

Amgen Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Amgen's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Price-to-Operating-Cash-Flow Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

16.04

12.92

13.92

14.62

18.29

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															14.62	15.08	11.05	13.65	18.29

Competitive Comparison of Amgen's Price-to-Operating-Cash-Flow

For the Drug Manufacturers - General subindustry, Amgen's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amgen's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Amgen's Price-to-Operating-Cash-Flow falls into.

Amgen Price-to-Operating-Cash-Flow Calculation

Amgen's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	255.16	/	15.76
	=	16.19

Amgen's Share Price of today is $255.16.
Amgen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.76.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Amgen Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Amgen's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Amgen (XSGO:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (XSGO:AMGN) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMG:Germany AMG:Germany AMG:Germany AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.